[시장보고서]동종 세포 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2031년)

동종 세포 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2031년)

Allogeneic Cell Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

상품코드 : 1568957

리서치사 : Persistence Market Research

발행일 : 2024년 10월

페이지 정보 : 영문 190 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,411,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,823,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,604,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 동종 세포 치료 세계 시장에 대한 종합적인 조사 보고서를 발표했습니다. 본 보고서에서는 시장촉진요인, 동향, 기회, 촉진요인, 과제 등의 중요한 시장 역학을 철저히 평가하여 시장 구조에 대한 상세한 통찰을 제공합니다. 이 조사 보고서는 2024-2031년까지 세계 동종세포 치료 시장 예측 성장 궤도를 개설하는 독점 데이터와 통계를 제공합니다.

주요 인사이트

동종세포 치료 시장 규모(2024년) : 4억 달러
예측 시장 규모(2031년) : 24억 달러
세계 시장 성장률(CAGR 2024-2031년) : 24.1%

동종 세포 치료 시장 - 보고 범위:

동종 세포 치료는 다양한 병리를 치료하기 위해 기증자의 세포를 사용하는 것으로, 암, 자가면역질환, 유전성 질환 등의 병리에 유망한 해결책을 기재하고 있습니다. 이 치료법은 병원, 연구 기관 및 전문 클리닉에서 빠르게 확산되고 있습니다. 동종세포 치료 시장은 종양학, 재생의료, 심혈관치료, 면역요법 등의 부문에 응용되어 줄기세포를 이용한 접근법에 의해 언메트 메디컬 요구에 부응하고 있습니다. 시장 성장의 원동력은 세포 공학의 진보, 만성 질환 증가, 혁신적인 치료 플랫폼의 개발입니다.

시장 성장 촉진요인:

세계의 동종세포 치료 시장은 암, 심혈관질환, 자가면역질환 등 만성질환의 이환율이 상승하고 첨단 치료법에 대한 수요가 높아지고 있는 등 몇 가지 중요한 요인들로 뒷받침됩니다. 세포 기반 치료법의 혁신은 신제품 규제 당국의 승인과 함께 시장 성장을 가속화하고 있습니다. 연구개발에 대한 투자가 증가하고 환자 유래 세포를 필요로 하지 않고 복잡한 병리에 대처할 수 있는 동종세포 치료의 가능성이 인식되고 있는 것도 시장 확대를 더욱 뒷받침하고 있습니다.

시장 성장 억제요인:

유망한 성장 전망에도 불구하고, 동종 세포 치료 시장은 규제상의 장애물, 높은 생산 비용, 세포 제조 및 유통 물류의 복잡성과 관련된 문제에 직면하고 있습니다. 임상시험에 대한 엄격한 규제 요건은 면역거부반응과 장기적인 안전성에 대한 우려와 함께 보급의 장벽이 되고 있습니다. 또한, 세포 치료 비용은 여전히 높으며, 특히 의료 예산에 제약이 있는 신흥 경제국에서의 이용을 제한하고 있습니다. 이러한 문제를 해결하려면 규제 기관, 제조업체 및 의료 제공업체를 포함한 이해 관계자가 협력하여 생산 공정를 간소화하고 비용을 절감해야합니다.

시장 기회:

동종 세포 치료 시장은 유전자 편집 기술의 진보, 맞춤형 의료의 상승, 세포 기반 연구에 대한 정부 자금 증가로 큰 성장 기회를 제공합니다. 세포치료 연구에 인공지능(AI)과 데이터 분석이 통합됨으로써 치료 성적이 최적화되고 신규 요법 시장 투입까지의 시간이 단축될 것으로 기대됩니다. 게다가 신경질환이나 자가면역질환 등 암 이외의 질환의 치료에 있어서 동종세포 치료의 응용이 확대되고 있는 것도 시장의 가능성을 넓히고 있습니다. 학술기관과 생명공학기업과의 전략적 공동연구 및 제휴는 기술 혁신을 추진하고 시장에서 리더십을 유지하는 데 필수적입니다.

이 보고서에서 다루는 주요 질문

동종세포 치료 시장의 세계적 성장을 견인하는 주요 요인은?
다양한 의료 환경에서 동종 세포 치료의 채택을 촉진하는 치료 부문은 무엇인가?
기술의 진보는 동종세포 치료 시장 경쟁 구도를 어떻게 바꾸고 있는가?
동종세포 치료시장에 공헌하고 있는 주요 진입기업은 누구이며 시장의 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
세계의 동종세포 치료 시장에서의 새로운 동향과 장래성은?

시장 규모(10억 달러)의 분석과 예측
- 과거 시장 규모(10억 달러) 분석, 2019-2023년
- 현재 시장 규모(10억 달러)의 분석과 예측, 2024-2031년
세계의 동종 세포 치료 시장 전망 : 치료 유형
- 소개/주요 조사 결과
- 과거 시장 규모(10억 달러) 분석, 치료 유형별, 2019-2023년
- 현재 시장 규모(10억 달러)의 분석과 예측, 치료 유형별, 2024-2031년
  - 줄기세포 치료
  - 비줄기세포 치료
시장의 매력 분석 : 치료 유형
세계의 동종 세포 치료 시장 전망 : 치료 영역
- 소개/주요 조사 결과
- 과거 시장 규모(10억 달러) 분석, 치료 영역별, 2019-2023년
- 현재 시장 규모(10억 달러)의 분석과 예측, 치료 영역별, 2024-2031년
  - 혈액 질환
  - 피부질환
  - 종양성 질환
  - 신경질환
  - 기타
시장의 매력 분석 : 치료 영역

제5장 세계의 동종 세포 치료 시장 전망 : 지역

2019-2023년에 있어서의 지역별 시장 규모(10억 달러)의 과거 분석
현재 시장 규모(10억 달러)의 분석과 예측, 지역별, 2024-2031년
- 북미
- 유럽
- 동아시아
- 남아시아와 오세아니아
- 라틴아메리카
- 중동 및 아프리카
시장의 매력 분석 :지역

제6장 북미의 동종세포 치료 시장 전망: 실적(2019-2023년)과 예측(2024-2031년)

제7장 유럽의 동종세포 치료 시장 전망: 실적(2019-2023년)과 예측(2024-2031년)

제8장 동아시아의 동종세포 치료 시장 전망: 실적(2019-2023년)과 예측(2024-2031년)

제9장 남아시아와 오세아니아의 동종세포 치료 시장 전망: 실적(2019-2023년)과 예측(2024-2031년)

제10장 라틴아메리카의 동종세포 치료 시장 전망: 실적(2019-2023년)과 예측(2024-2031년)

제11장 중동 및 아프리카의 동종 세포 치료 시장 전망: 실적(2019-2023년)과 예측(2024-2031년)

제12장 경쟁 구도

시장 점유율 분석, 2024년
시장 구조
- 시장별 경쟁 강도 매핑
- 경쟁 대시보드
기업 프로파일(상세 - 개요, 재무, 전략, 최근 동향)
- SSM Cardinal Glennon Children's Medical Center
- Cleveland Cord Blood Center
- Duke University School of Medicine
- New York Blood Center
- Clinimmune Labs, University of Colorado Cord Blood Bank
- MD Anderson Cord Blood Bank
- LifeSouth Community Blood Centers, Inc.
- Bloodworks Northwest
- JCR Pharmaceuticals Co., Ltd.
- Sumitomo Pharma Co., Ltd.
- Atara Biotherapeutics
- Mallinckrodt Pharmaceuticals
- Tego Science Inc
- Takeda Pharmaceutical Company Limited
- STEMPEUTICS RESEARCH PVT LTD
- Biosolution Co., Ltd.
- MEDIPOST Co., Ltd.

제13장 부록

조사 방법
조사의 전제
두자어 및 약어

JHS

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for Allogeneic Cell Therapy. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global allogeneic cell therapy market from 2024 to 2031.

Key Insights:

Allogeneic Cell Therapy Market Size (2024E):US$0.4 Bn
Projected Market Value (2031F): US$2.4 Bn
Global Market Growth Rate (CAGR 2024 to 2031):24.1%

Allogeneic Cell Therapy Market - Report Scope:

Allogeneic cell therapy involves the use of cells from a donor to treat various medical conditions, offering a promising solution for conditions like cancer, autoimmune diseases, and genetic disorders. This therapy is rapidly gaining traction across hospitals, research institutions, and specialized clinics. The allogeneic cell therapy market spans applications in oncology, regenerative medicine, cardiovascular treatment, and immunotherapy, addressing unmet medical needs through stem cell-based approaches. Market growth is driven by advancements in cell engineering, the increasing incidence of chronic diseases, and the development of innovative therapeutic platforms.

Market Growth Drivers:

The global allogeneic cell therapy market is propelled by several key factors, including the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, which are fueling demand for advanced therapies. Technological innovations in cell-based therapies, coupled with regulatory approvals of novel products, are accelerating market growth. Increased investments in R&D and the growing recognition of allogeneic cell therapy's potential to address complex medical conditions without the need for patient-derived cells further support market expansion.

Market Restraints:

Despite the promising growth outlook, the allogeneic cell therapy market faces challenges related to regulatory hurdles, high production costs, and logistical complexities of cell manufacturing and distribution. Stringent regulatory requirements for clinical trials, coupled with concerns over immune rejection and long-term safety, present barriers to widespread adoption. Additionally, the cost of cell therapies remains high, limiting accessibility, particularly in emerging economies with constrained healthcare budgets. Addressing these challenges requires collaborative efforts between stakeholders, including regulatory bodies, manufacturers, and healthcare providers, to streamline production processes and reduce costs.

Market Opportunities:

The allogeneic cell therapy market presents significant growth opportunities driven by advancements in gene editing technologies, the rise of personalized medicine, and increased government funding for cell-based research. The integration of artificial intelligence (AI) and data analytics into cell therapy research is expected to optimize treatment outcomes and reduce time-to-market for new therapies. Furthermore, the growing application of allogeneic cell therapies in treating diseases beyond oncology, such as neurological disorders and autoimmune diseases, expands market potential. Strategic collaborations and partnerships with academic institutions and biotechnology companies are essential to drive innovation and maintain market leadership.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the allogeneic cell therapy market globally?
Which therapeutic areas are driving allogeneic cell therapy adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the allogeneic cell therapy market?
Who are the key players contributing to the allogeneic cell therapy market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global allogeneic cell therapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global allogeneic cell therapy market, including Mesoblast Limited, JCR Pharmaceuticals Co., Ltd., and Athersys, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced cell therapies for diverse applications such as regenerative medicine and oncology. Collaborations with research institutions, pharmaceutical companies, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances treatment outcomes in the rapidly evolving cell therapy landscape.

Key Companies Profiled:

Mesoblast Limited
JCR Pharmaceuticals Co., Ltd.
Athersys, Inc.
AlloVir
Gamida Cell Ltd.
Atara Biotherapeutics, Inc.
Celyad Oncology

Allogeneic Cell Therapy Market Segmentation

By Therapy Type

Stem Cell Therapies
Non-stem Cell Therapies

By Therapeutic Area

Hematological Disorders
Dermatological Disorders
Oncological Disorders
Neurological Disorders

By Region

North America
Europe
Asia Pacific
the Middle East and Africa
Latin America

1. Executive Summary

1.1. Global Allogeneic Cell Therapy Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Epidemiology - Disease Prevalence and Incidence
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis

4. Global Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
4.3. Global Allogeneic Cell Therapy Market Outlook: Therapy Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Therapy Type, 2019-2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  - 4.3.3.1. Stem Cell Therapies
  - 4.3.3.2. Non-stem Cell Therapies
4.4. Market Attractiveness Analysis: Therapy Type
4.5. Global Allogeneic Cell Therapy Market Outlook: Therapeutic Area
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019-2023
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  - 4.5.3.1. Hematological Disorders
  - 4.5.3.2. Dermatological Disorders
  - 4.5.3.3. Oncological Disorders
  - 4.5.3.4. Neurological Disorders
  - 4.5.3.5. Others
4.6. Market Attractiveness Analysis: Therapeutic Area

5. Global Allogeneic Cell Therapy Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 6.3.1. By Country
- 6.3.2. By Therapy Type
- 6.3.3. By Therapeutic Area
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 6.4.1. U.S.
- 6.4.2. Canada
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
- 6.5.1. Stem Cell Therapies
- 6.5.2. Non-stem Cell Therapies
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
- 6.6.1. Hematological Disorders
- 6.6.2. Dermatological Disorders
- 6.6.3. Oncological Disorders
- 6.6.4. Neurological Disorders
- 6.6.5. Others
6.7. Market Attractiveness Analysis

7. Europe Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 7.3.1. By Country
- 7.3.2. By Therapy Type
- 7.3.3. By Therapeutic Area
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 7.4.1. Germany
- 7.4.2. France
- 7.4.3. U.K.
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Turkiye
- 7.4.8. Rest of Europe
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
- 7.5.1. Stem Cell Therapies
- 7.5.2. Non-stem Cell Therapies
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
- 7.6.1. Hematological Disorders
- 7.6.2. Dermatological Disorders
- 7.6.3. Oncological Disorders
- 7.6.4. Neurological Disorders
- 7.6.5. Others
7.7. Market Attractiveness Analysis

8. East Asia Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 8.3.1. By Country
- 8.3.2. By Therapy Type
- 8.3.3. By Therapeutic Area
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. South Korea
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
- 8.5.1. Stem Cell Therapies
- 8.5.2. Non-stem Cell Therapies
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
- 8.6.1. Hematological Disorders
- 8.6.2. Dermatological Disorders
- 8.6.3. Oncological Disorders
- 8.6.4. Neurological Disorders
- 8.6.5. Others
8.7. Market Attractiveness Analysis

9. South Asia & Oceania Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 9.3.1. By Country
- 9.3.2. By Therapy Type
- 9.3.3. By Therapeutic Area
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 9.4.1. India
- 9.4.2. Southeast Asia
- 9.4.3. ANZ
- 9.4.4. Rest of South Asia & Oceania
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
- 9.5.1. Stem Cell Therapies
- 9.5.2. Non-stem Cell Therapies
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
- 9.6.1. Hematological Disorders
- 9.6.2. Dermatological Disorders
- 9.6.3. Oncological Disorders
- 9.6.4. Neurological Disorders
- 9.6.5. Others
9.7. Market Attractiveness Analysis

10. Latin America Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 10.3.1. By Country
- 10.3.2. By Therapy Type
- 10.3.3. By Therapeutic Area
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 10.4.1. Brazil
- 10.4.2. Mexico
- 10.4.3. Rest of Latin America
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
- 10.5.1. Stem Cell Therapies
- 10.5.2. Non-stem Cell Therapies
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
- 10.6.1. Hematological Disorders
- 10.6.2. Dermatological Disorders
- 10.6.3. Oncological Disorders
- 10.6.4. Neurological Disorders
- 10.6.5. Others
10.7. Market Attractiveness Analysis

11. Middle East & Africa Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 11.3.1. By Country
- 11.3.2. By Therapy Type
- 11.3.3. By Therapeutic Area
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 11.4.1. GCC Countries
- 11.4.2. Egypt
- 11.4.3. South Africa
- 11.4.4. Northern Africa
- 11.4.5. Rest of Middle East & Africa
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
- 11.5.1. Stem Cell Therapies
- 11.5.2. Non-stem Cell Therapies
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
- 11.6.1. Hematological Disorders
- 11.6.2. Dermatological Disorders
- 11.6.3. Oncological Disorders
- 11.6.4. Neurological Disorders
- 11.6.5. Others
11.7. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2024
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. SSM Cardinal Glennon Children's Medical Center
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Products
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Cleveland Cord Blood Center
  - 12.3.2.1. Overview
  - 12.3.2.2. Segments and Products
  - 12.3.2.3. Key Financials
  - 12.3.2.4. Market Developments
  - 12.3.2.5. Market Strategy
- 12.3.3. Duke University School of Medicine
  - 12.3.3.1. Overview
  - 12.3.3.2. Segments and Products
  - 12.3.3.3. Key Financials
  - 12.3.3.4. Market Developments
  - 12.3.3.5. Market Strategy
- 12.3.4. New York Blood Center
  - 12.3.4.1. Overview
  - 12.3.4.2. Segments and Products
  - 12.3.4.3. Key Financials
  - 12.3.4.4. Market Developments
  - 12.3.4.5. Market Strategy
- 12.3.5. Clinimmune Labs, University of Colorado Cord Blood Bank
  - 12.3.5.1. Overview
  - 12.3.5.2. Segments and Products
  - 12.3.5.3. Key Financials
  - 12.3.5.4. Market Developments
  - 12.3.5.5. Market Strategy
- 12.3.6. MD Anderson Cord Blood Bank
  - 12.3.6.1. Overview
  - 12.3.6.2. Segments and Products
  - 12.3.6.3. Key Financials
  - 12.3.6.4. Market Developments
  - 12.3.6.5. Market Strategy
- 12.3.7. LifeSouth Community Blood Centers, Inc.
  - 12.3.7.1. Overview
  - 12.3.7.2. Segments and Products
  - 12.3.7.3. Key Financials
  - 12.3.7.4. Market Developments
  - 12.3.7.5. Market Strategy
- 12.3.8. Bloodworks Northwest
  - 12.3.8.1. Overview
  - 12.3.8.2. Segments and Products
  - 12.3.8.3. Key Financials
  - 12.3.8.4. Market Developments
  - 12.3.8.5. Market Strategy
- 12.3.9. JCR Pharmaceuticals Co., Ltd.
  - 12.3.9.1. Overview
  - 12.3.9.2. Segments and Products
  - 12.3.9.3. Key Financials
  - 12.3.9.4. Market Developments
  - 12.3.9.5. Market Strategy
- 12.3.10. Sumitomo Pharma Co., Ltd.
  - 12.3.10.1. Overview
  - 12.3.10.2. Segments and Products
  - 12.3.10.3. Key Financials
  - 12.3.10.4. Market Developments
  - 12.3.10.5. Market Strategy
- 12.3.11. Atara Biotherapeutics
  - 12.3.11.1. Overview
  - 12.3.11.2. Segments and Products
  - 12.3.11.3. Key Financials
  - 12.3.11.4. Market Developments
  - 12.3.11.5. Market Strategy
- 12.3.12. Mallinckrodt Pharmaceuticals
  - 12.3.12.1. Overview
  - 12.3.12.2. Segments and Products
  - 12.3.12.3. Key Financials
  - 12.3.12.4. Market Developments
  - 12.3.12.5. Market Strategy
- 12.3.13. Tego Science Inc
  - 12.3.13.1. Overview
  - 12.3.13.2. Segments and Products
  - 12.3.13.3. Key Financials
  - 12.3.13.4. Market Developments
  - 12.3.13.5. Market Strategy
- 12.3.14. Takeda Pharmaceutical Company Limited
  - 12.3.14.1. Overview
  - 12.3.14.2. Segments and Products
  - 12.3.14.3. Key Financials
  - 12.3.14.4. Market Developments
  - 12.3.14.5. Market Strategy
- 12.3.15. STEMPEUTICS RESEARCH PVT LTD
  - 12.3.15.1. Overview
  - 12.3.15.2. Segments and Products
  - 12.3.15.3. Key Financials
  - 12.3.15.4. Market Developments
  - 12.3.15.5. Market Strategy
- 12.3.16. Biosolution Co., Ltd.
  - 12.3.16.1. Overview
  - 12.3.16.2. Segments and Products
  - 12.3.16.3. Key Financials
  - 12.3.16.4. Market Developments
  - 12.3.16.5. Market Strategy
- 12.3.17. MEDIPOST Co., Ltd.
  - 12.3.17.1. Overview
  - 12.3.17.2. Segments and Products
  - 12.3.17.3. Key Financials
  - 12.3.17.4. Market Developments
  - 12.3.17.5. Market Strategy

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations